Literature DB >> 32013627

The dry powder inhaler features of the Easyhaler that benefit the management of patients.

Henry Chrystyn1, Federico Lavorini2.   

Abstract

Introduction: Inhaled therapies are likely to continue to dominate asthma and chronic obstructive pulmonary disease treatment. Dry powder inhalers (DPIs) have several advantages over pressurized metered-dose inhaler (pMDIs), that are most frequently marketed world-wide, but often difficult to use. This literature search focus on DPI features, with respect to Easyhaler, that may affect their use and patients' clinical benefit.Areas covered: DPIs are breath-actuated, easy to use, convenient to use, and more environmentally friendly. During inhalation, the formulation in a DPI is disaggregated by a turbulent airflow energy to generate particles with the greatest likelihood of deposition into the airways. The resistance among DPIs varies from low to high and those with high resistance are wrongly considered as difficult to use. Multidose reservoir-type DPIs have been developed to efficiently deliver a wide range of medications, including the fixed-dose combination of budesonide and formoterol. Easyhaler® shares a similar shape with pMDIs and, as other DPIs, its performance is unaffected by environmental and storage conditions. Due to Easyhaler internal design, dose emission is consistent irrespective of the inhalation flow used by each patient.Expert opinion: Easyhaler® may be considered one of the most convenient inhalers, for daily use, in patients with asthma or COPD.

Entities:  

Keywords:  Asthma; COPD; Easyhaler; dose emission; dry powder inhalers; inhalation flow; inhaler resistance

Year:  2020        PMID: 32013627     DOI: 10.1080/17476348.2020.1721286

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  3 in total

Review 1.  Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices.

Authors:  Tushar Saha; Miguel E Quiñones-Mateu; Shyamal C Das
Journal:  Int J Pharm       Date:  2022-07-20       Impact factor: 6.510

Review 2.  Narrative Review of the Role of Patient-Reported Outcomes and Inhaler Handling Errors in the Control of Asthma and COPD.

Authors:  Raúl De Simón Gutiérrez; Raúl Piedra Castro
Journal:  Curr Allergy Asthma Rep       Date:  2022-09-10       Impact factor: 4.919

3.  Preference for Easyhaler® Over Previous Dry Powder Inhalers in Asthma Patients: Results of the DPI PREFER Observational Study.

Authors:  Francisco Javier Alvarez-Gutiérrez; Ana Gómez-Bastero Fernández; Juan Francisco Medina Gallardo; Carlos Campo Sien; Paula Rytilä; Julio Delgado Romero
Journal:  Patient Prefer Adherence       Date:  2021-02-16       Impact factor: 2.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.